Researchers are testing a fresh way to heal hearts after a heart attack by turning limb muscles into factories that send an inactive repair protein to the injured organ, where it activates and encourages recovery without needing direct injections into the heart.
Adult human hearts have very limited regenerative ability, which is one reason heart attacks often lead to permanent scarring and long-term decline. “The heart is one of the organs with the least ability to regenerate,” said Ke Cheng, the study’s lead author. Newborn hearts can briefly regenerate, a clue researchers used to design this therapy.
“The neonatal heart spontaneously produces more of this molecule after a heart attack,” Cheng said. “The adult can’t produce a sufficient amount, so we found a way to supplement this to the heart.” The team focused on a naturally occurring protein called ANP that acts as a repair mechanism for the heart.
ANP itself can’t be delivered directly as a drug because it breaks down in the bloodstream within minutes, long before it reaches damaged heart tissue. To get around that hurdle, the researchers use a specialized RNA injection into skeletal muscle in the arm or leg. That muscle is instructed to produce a dormant or “sleeping” version of ANP that circulates safely until it reaches the heart.
Once the sleeping protein arrives at injured heart tissue, a specific enzyme there flips it into an active form, so the repair signal turns on only where it’s needed. “The whole idea is that we learn from nature.” This targeted activation aims to reduce off-target effects and concentrate the healing process at the site of damage.
Preclinical work in both small and large animals showed promising results: a single limb injection reduced scarring and led to measurable improvements in heart function. Because the researchers used self-amplifying RNA that replicates inside cells, the muscle kept producing the therapeutic protein for at least four weeks. That durability means a single treatment could cover a critical recovery window after injury.
The approach also proved somewhat forgiving in timing. The therapy remained effective when administered a week after the simulated heart attack, which matters for real-world patients who might not receive care immediately. “The patient doesn’t have to go to the hospital today and tomorrow,” Cheng said, noting the benefit of avoiding risky procedures that inject therapies directly into the heart muscle.
Limitations are real and acknowledged: these results come from animal models, and human hearts are more complex. Clinical trials will be needed to confirm that the method works the same way in people and to determine optimal dosing and timing. Researchers will also need to confirm that long-term protein production from the RNA does not cause unintended problems elsewhere in the body.
Safety questions include the potential for prolonged RNA activity to trigger immune responses or unwanted protein effects in non-target tissues. The research team highlighted the advantage of a locally produced, dormant molecule that only activates in damaged cardiac tissue, but careful monitoring will be key as studies move toward human testing. Regulators will want clear evidence on both efficacy and the absence of collateral harm.
If future trials succeed, this technique could shift how we think about cardiac repair by outsourcing production of therapeutic proteins to skeletal muscle and relying on local activation at the heart. That would offer a less invasive option than direct cardiac injections and could extend the treatment window for many patients. For now, the work is an intriguing step toward smarter, more targeted therapies that borrow from the biology of newborn hearts to help adults recover.
